📰 Arcus Bioscience News
Page 5 - Arcus Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Arcus Bioscience. Real-time updates on events, politics, business and more.
June 26, 2023
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’...
June 26, 2023
HAYWARD, Calif.--(BUSINESS WIRE)--Jun 26, 2023--
June 9, 2023
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the... | June 10, 2023
June 9, 2023
FinancialContent fully hosted finance channel
June 3, 2023
– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC... | June 3, 2023
June 3, 2023
– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC... | June 7, 2023
June 3, 2023
FinancialContent fully hosted finance channel
June 3, 2023
FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Jun 3, 2023--
June 3, 2023
– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC –– Objective Response Rate (ORR) Improved in Both Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy –– Re...
May 30, 2023
FinancialContent fully hosted finance channel